[{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Series D Financing","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ CG Oncology","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ CG Oncology"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Merck & Co"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CG Oncology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncology \/ Merck & Co"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CG Oncology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncology \/ Merck & Co"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Foresite Capital","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Foresite Capital"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.44,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Morgan Stanley"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Morgan Stanley"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"CG0070","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CG Oncology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncology \/ Merck & Co"}]
Find Clinical Drug Pipeline Developments & Deals by CG Oncology
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
